Denali

Read more
Ryan Watts's photo - President & CEO of Denali

President & CEO

Ryan Watts

CEO Approval Rating

100/100

Founded:

2013

Status:

PublicIndependent CompanyNASDAQDNLI

DENALI TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Denali's company profile
Ryan Watts's photo - President & CEO of Denali

Ryan Watts

President & CEO

100/100
179
$597M
$357.1M
View Profile
1
Denali's Competitor - Alector logo
Arnon Rosenthal's photo - President & CEO of Alector

Arnon Rosenthal

President & CEO

82/100
78
$407.5M
$24.6M
View Profile
2
Denali's Competitor - Cortexyme logo
Casey C. Lynch's photo - Chairman & CEO of Cortexyme

Casey C. Lynch

Chairman & CEO

82/100
38
$308.1M
View Profile
3
Denali's Competitor - Alzheon logo
Martin Tolar's photo - President & CEO of Alzheon

Martin Tolar

President & CEO

85/100
30
$94.3M
$8M
View Profile
4
Denali's Competitor - Compass Therapeutics logo
Thomas J. Schuetz's photo - Co-Founder & CEO of Compass Therapeutics

Thomas J. Schuetz

Co-Founder & CEO

89/100
31
$291.6M
$8.5M
View Profile
5
Denali's Competitor - Verge Genomics logo
Alice Zhang's photo - Co-Founder & CEO of Verge Genomics

Alice Zhang

Co-Founder & CEO

87/100
35
$36M
$6M
View Profile
6
Denali's Competitor - Design Therapeutics logo
Joao Siffert's photo - President & CEO of Design Therapeutics

Joao Siffert

President & CEO

90/100
17
$410.5M
View Profile
7
Denali's Competitor - Travecta logo
Charles S. Ryan's photo - President & CEO of Travecta

Charles S. Ryan

President & CEO

90/100
25
$15M
$2.9M
View Profile
8
Denali's Competitor - Tetra logo
Chad A. Coberly's photo - CEO of Tetra

Chad A. Coberly

CEO

90/100
25
- -
$3.4M
View Profile
9
Denali's Competitor - XWPharma logo
Leonard Blum's photo - President & CEO of XWPharma

Leonard Blum

President & CEO

90/100
15
$62.5M
$ < 1M
View Profile
10
Denali's Competitor - Lucid Psycheceuticals logo
Lakshmi P. Kotra's photo - Co-Founder & CEO of Lucid Psycheceuticals

Lakshmi P. Kotra

Co-Founder & CEO

90/100
10
- -
$2M
View Profile
11
Denali's Competitor - Yumanity logo
Richard Peters's photo - President & CEO of Yumanity

Richard Peters

President & CEO

90/100
44
$103.8M
$6M
View Profile
12
Denali's Competitor - Lysosomal Therapeutics logo
Kees Been's photo - President & CEO of Lysosomal Therapeutics

Kees Been

President & CEO

89/100
38
$38M
$4.4M
View Profile

Missing a competitor? Contribute!

Alector is Denali's top competitor. Alector is a Public company that was founded in South San Francisco, California in 2013. Alector operates in the Biotechnology industry. Alector has 5 more employees vs. Denali.

Cortexyme has been one of Denali's top competitors. Cortexyme is headquartered in South San Francisco, California, and was founded in 2012. Cortexyme is in the Biotechnology field. Cortexyme generates NaN% the revenue of Denali.

Alzheon is perceived as one of Denali's biggest rivals. Alzheon was founded in 2013 in Framingham, Massachusetts. Alzheon competes in the Biotechnology field. Alzheon generates $349.1M less revenue than Denali.

Denali Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$357.1M

Denali's revenue is the ranked 1st among it's top 10 competitors. The top 10 competitors average 35.4M. Over the last four quarters, Denali's revenue has grown by 144.2%. Specifically, in Q2 2021's revenue was $22.9M; in Q1 2021, it was $7.9M; in Q4 2020, it was $316.8M; in Q3 2020, Denali's revenue was $9.4M.

Denali Acquisitions

No recent acquisitions found related to Denali

Denali Funding History

Since Denali was founded in 2013, it has participated in 3 rounds of funding. In total Denali has raised $597.0M. Denali's last funding round was on Dec 2017 for a total of $250.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
Dec 2017
$250M
-
Series B
Aug 2016
$130M
Series A
May 2015
$217M

Since Denali was founded in 2013, it has participated in 3 rounds of funding. In total Denali has raised $597.0M. Denali's last funding round was on Dec 2017 for a total of $250.0M

Denali Investments

No recent investments found related to Denali

Denali News

September 3, 2021Zacks

Can It Continue?

Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a l... See more »
August 4, 2021Zacks

Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Lags Revenue Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -35.14% and -28.56%, resp... See more »
July 30, 2021Zacks

Will Denali Therapeutics Inc. (DNLI) Report Negative Q2 Earnings? What You Should Know

Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for ... See more »
July 26, 2021Endpoints News

Denali slips as a snapshot of early data raises some troubling questions on its pioneering blood-brain barrier neuro work

Denali Therapeutics had drummed up considerable hype for their blood-brain barrier technology since l... See more »
July 26, 2021MarketScreener

Denali Therapeutics Announces Positive Interim Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with the Lysosomal Storage Disease Hunter Syndrome (MPS II) (Form 8-K)

(marketscreener.com) Denali Therapeutics Announces Positive Interim Data from Phase 1/2 Study with ET... See more »
July 26, 2021Benzinga

Denali's Brain-Penetrant Enzyme Therapy Shows Durable Effect With CNS Impact In Hunter Syndrome

Denali Therapeutics Inc (NASDAQ: DNLI) announced additional interim data from a Phase 1/2 study evalu... See more »

Denali Press Releases

February 25, 2021StreetInsider

Denali Therapeutics Reports Full Year 2020 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) --...... See more »
January 11, 2021GlobalNewswire

Denali Therapeutics Announces Appointment of Nancy Thornberry to Board of Directors

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI... See more »
November 10, 2020GlobalNewswire

Denali Therapeutics Announces First Human Biomarker Proof of Concept for Its Transport Vehicle (TV) Technology Achieved in Phase 1/2 Study of ETV:IDS (DNL310) in Hunter Syndrome (MPS II)

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI... See more »
October 15, 2020GlobeNewswire

Denali Therapeutics to Highlight Progress Across Broad Biotherapeutics Portfolio for Neurodegeneration Enabled by Its Blood-Brain Barrier (BBB) TV Platform at Virtual R&D Day Today

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI... See more »
August 6, 2020centralcharts

Denali Therapeutics Announces Decision to Advance DNL151 into Late Stage Clinical Studies in Parkinson's Patients

DNL151 selected to advance into two late stage studies in Parkinson's disease in patients with a kina... See more »
July 29, 2020GlobeNewswire

Denali Therapeutics Announces Phase 1b Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in COVID-19 Patients

SOUTH SAN FRANCISCO, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI... See more »

Social Media

Denali Headquarters

161 Oyster Point Boulevard

South San Francisco, California94080

650-866-8548

Driving Directions »

Trending Companies

Denali Summary

ABOUT

Overview

Denali is a California-based biotechnology company that develops and commercializes novel therapies for the treatment of neurodegenerative diseases. Denali was founded in 2013. Denali's headquarters is located in South San Francisco, California, USA 9...

CEO

Denali's President & CEO, Ryan Watts, currently has an approval rating of 100%. Denali's primary competitors are Alector, Cortexyme & Alzheon.

Frequently Asked Questions about Denali

  1. When was Denali founded?

    Denali was founded in 2013
  2. Who is Denali's CEO?

    Denali's CEO is Ryan Watts
  3. How much revenue does Denali generate?

    Denali generates $357.1M in revenue
  4. How much funding does Denali have?

    Denali has historically raised $597M in funding
  1. Where is Denali's headquarters?

    Denali's headquarters is in South San Francisco California, USA
  2. How many employees does Denali have?

    Denali has 179 employees
  3. What sector does Denali operate in?

    Denali is in Biotechnology
  4. Who are Denali's competitors?

    Denali's top competitors are Alector, Cortexyme, Alzheon